Eli Lilly Has Agreed To Acquire DICE Therapeutics For $48 Per Share In Cash (An Aggregate Of Approximately $2.4B)
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has agreed to acquire DICE Therapeutics for $48 per share in cash, totaling approximately $2.4 billion.
June 20, 2023 | 10:47 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Eli Lilly's acquisition of DICE Therapeutics for $2.4 billion may impact its short-term stock price.
Eli Lilly's acquisition of DICE Therapeutics may have a neutral short-term impact on its stock price. The acquisition could be seen as a strategic move to expand its portfolio, but the $2.4 billion price tag may also raise concerns about overpaying.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100